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The objective of the study is to evaluate 10 years of down-staging strategy for liver transplantation 
(LT) with a median follow-up of 5 years. Data on long-term results are poor and less information is 
available for hepatocellular carcinoma (HCC) non-responder patients or those ineligible for down-
staging. The outcome of 308 HCC candidates and the long-term results of 231 LTs for HCC performed 
between 2003 and 2013 were analyzed. HCCs were divided according to tumor stage and response to 
therapy: 145 patients were T2 (metering Milan Criteria, MC), 43 were T3 successfully down-staged to 
T2 (Down-Achieved), 20 were T3 not fully down-staged to T2 (Down-not Achieved), and 23 patients 
were T3 not receiving down-staging treatments (No-Down). The average treatment effect (ATE) of LT 
for T3 tumors was estimated using the outcome of 535 T3 patients undergoing non-LT therapies, using 
inverse probability weighting regression adjustment. The 24-month drop-out rate during waiting time 
was significantly higher in the down-staging groups: 27.6% vs. 9.2%, p < 0.005. After LT, the tumor 
recurrence rate was significantly different: MC 7.6%, Down-Achieved 20.9%, Down-not Achieved 
31.6%, and No-Down 30.4% (p < 0.001). The survival rates at 5 years were: 63% in Down-Achieved, 62% 
in Down-not Achieved, 63% in No-Down, and 77% in MC (p = n.s.). The only variable related to a better 
outcome was the effective down-staging to T2 at the histological evaluation of the explanted liver: 
recurrence rate = 7.8% vs. 26% (p < 0.001) and 5-year patient survival = 76% vs. 67% (p < 0.05). The 
ATE estimation showed that the mean survival of T3-LT candidates was significantly better than that 
of T3 patients ineligible for LT [83.3 vs 39.2 months (+44.6 months); p < 0.001]. Long term outcome of 
T3 down-staged candidates was poorer than that of MC candidates, particularly for cases not achieving 
down-staging. However, their survival outcome was significantly better than that achieved with non-
transplant therapies.
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The Milan Criteria (MC), proposed in 19961, have paved the way for liver transplantation (LT) in patients with 
hepatocellular carcinoma (HCC). The selection of patients with a solitary tumor ≤5 cm or up to 3 tumors with the 
largest being ≤3 cm in diameter, allows a 5-year survival of 70% and a recurrence rate of only 10%, thus becoming 
comparable to outcomes achievable in non-oncological indications for LT1,2, and accomplishing the concept of 
“equity”.
However, MC precludes access to LT of some patients with a potentially good outcome, and many groups 
have investigated how these criteria can be expanded, without affecting patient survival and tumor recurrence3,4. 
One possibility is to expand the criteria based on the slightly extended tumor burden, an example of this strategy 
being the “up-to-seven” rule (the sum of the number of nodules plus the size in cm of the largest one cannot 
exceed seven), derived from a large retrospective database5. Another way to expand the criteria for transplan-
tation relies on the selection of less aggressive tumors responding to the treatment, the so called down-staging 
strategy. This opens the LT doors to patients with HCC outside MC (but within predefined maximum tumor 
burdens) who have been variously but successfully treated in order to reduce the tumor burden and, possibly, 
re-entering the framework of MC. In 2002, our group designed a down-staging protocol based on different neo-
adjuvant treatments aimed at bringing the tumor back within MC limits, which was prospectively applied in our 
clinical practice. According to an intention-to-treat analysis, the LT outcome of down-staged patients was found 
to be comparable to that of recipients originally meeting the MC in terms of 3-year survival6.
Based on the good results obtained in this exploratory study and by another study by the University of 
California San Francisco (UCSF) where a quite similar strategy was adopted7, a recent international consensus 
conference on LT for HCC addressed this issue publishing the following recommendations: “LT can be consid-
ered after successful down-staging, the survival of successfully down-staged patients should be comparable to 
HCC patients within MC from the beginning. The criteria for successful down-staging should include tumor size 
and number of active lesions, although no common agreement is reached on the threshold”8.
The UCSF group updated their population study after a median follow-up of more than 3 years and confirmed 
its previous results, although some categories of patients (4–5 lesions of HCCs) did not have definitive evidence 
due to the small number of cases9. Moreover, open questions remained about the patients transplanted without 
successful down-staging or not suitable for down-staging10.
Since post-transplant HCC recurrence may occur even many years after surgery and recurrent cases may sur-
vive for more than 1–2 years11,12, how much such recurrences can impair the long-term success of down-staging 
strategies has not been defined. In fact, prospective long-term results of LT performed after down-staging proce-
dures are limited.
In order to give further insight on the long-term results of LT performed in the setting of HCC down-staging, 
the present study analyses our ten years’ experience, including a follow-up of 5 years post-LT.
Materials and Methods
Study population and bridge treatment procedures. The study includes 308 cases with HCC listed for 
LT in our center between 2003 and 2013 and the median post-LT follow-up was 5 years. The series we described 
in 20086 was therefore updated and all new consecutive cases were added. The local medical ethics committee 
of Sant’Orsola-Malpighi Hospital - University of Bologna approved this retrospective observational study and 
informed consent was signed by enrolled patients.
The diagnosis of HCC was performed according to international guidelines recommendations released in the 
corresponding period of diagnosis13,14. When the imaging work up led to dubious results, a biopsy was performed 
on the target lesion. The retrospective review of all the lesions confirmed that they were LIRAD 5 nodules15.
Down-staging protocol. 
•	 The criteria approved by the Bologna liver transplant Committee were: single HCC ≤8 cm; bifocal HCC, each 
≤5 cm; multiple HCC with ≤5 nodules, each ≤4 cm and a total tumor diameter ≤12 cm.
•	 All the cases had to meet MC at the end of the down-staging procedures, including both newly developed 
nodules and those still active, the diameter of which was calculated including the necrotic part. The total 
number of nodules, treated or not treated, and present at the beginning or developing later, could not exceed 
the limit approved for the protocol.
•	 The type of neoadjuvant treatment was decided case-by-case and by a multidisciplinary team including hepa-
tologists, liver surgeons, radiologists and pathologists, following the available guidelines and our previous 
experience6,13,14,16–18.
•	 The possible options were: liver resection (LR), transarterial chemo-embolization (TACE), percutaneous eth-
anol injection (PEI), percutaneous radiofrequency ablation (RFA). The cases of liver resection with radical 
intent, with no evidence of disease and R0 were not included in the waiting list and in the down-stage group.
•	 After successful down-staging, a minimum follow-up of 3 months of permanence within the MC without 
additional treatments was considered necessary to include patients in the waiting list.
•	 Alpha-fetoprotein level (AFP) had to remain <400 ng/dL during the waiting time.
•	 Macro-vascular or biliary invasion by the tumor were exclusion criteria.
All listed patients were followed-up with ultrasonography (US) or computed tomography (CT) every 3 
months. At the follow-up, the size of active nodules (presenting contrast enhancement at imaging) was measured, 
also including the necrotic portion. Both down-staged active nodules and new nodules that appeared during the 
waiting time were considered in establishing whether the MC were met. At any time of the waiting list period, the 
total number of nodules (treated or not, present at the beginning or developing subsequently) could not exceed 
the number approved in the protocol.
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The listed patients with HCC received priority by adding extra points to the biochemical MELD (model for 
end stage liver disease) score, according to their tumor stage and the waiting time, as previously reported16,17.
Exceptions to the down-staging protocol. After 2006, our Scientific Committee decided to also eval-
uate cases meeting our down-staging criteria, but unable to be effectively down-staged at imaging evaluation or 
not amenable to down-staging due to impaired liver function. These patients were discussed case-by-case during 
the multidisciplinary meeting and selected for LT in order to explore the outcome of these new HCC categories 
with respect to our previous study.
The study was approved by the local institutional review committee. All the procedures were performed upon 
approval by our ethics committee and collection of informed consent from all the patients.
Study groups. Following the down-staging protocol and the exceptions, four groups were created on the 
basis of the pre-operative imaging:
 (1) 186 HCCs always meeting the conventional (Milan) criteria (T2), who received, or not, pre-operative 
bridge treatments (MC);
 (2) 65 HCCs initially exceeding the conventional criteria (T3), but meeting the criteria for enrolment in 
our down-staging protocol and who were successfully down-staged to T2 at the last pre-LT imaging 
(Down-Achieved);
 (3) 30 HCCs initially not meeting the conventional criteria (T3), but within the criteria for enrolment in our 
down-staging protocol and who failed to achieve a down-staging to T2 at the last pre-LT imaging (Down-
not Achieved);
 (4) 27 HCCs exceeding the conventional criteria (T3), but within the criteria for the enrolment in our 
down-staging protocol and who did not receive any antitumor down-staging therapy, due to their impaired 
liver function (No-Down).
Statistical analysis. Fisher’s exact test, Mann-Whitney test or Chi-square test were applied, as appropriate. 
The intention to treat the survival of patients was calculated by the Kaplan-Meyer method, starting from the date 
of enrolment to the date of death or the most recent follow-up visit. The post-transplant survival was calculated 
by the Kaplan-Meyer method, starting from the date of LT to the date of death or the most recent follow-up visit6. 
The difference between survivals was tested by the Log-rank test. The follow-up started in January 2003 and 
ended in December 2016. Statistical analysis was performed with SPSS (SPSS Base 10.0; Application Guide, SPSS 
Inc., Chicago, IL, 1998).
Statistical analysis to compare the efficacy of liver transplantation vs. other treatments. The 
Italian Liver Cancer (ITA.LI.CA) database of 2014 was used to compare the outcomes of the present study pop-
ulation with a population in which transplantation was not performed. From this prospective registry of HCC 
patients consecutively diagnosed and followed by 24 Italian medical institutions, only patients with complete data 
and with a T3 tumor were retained for comparison with the current T3 candidates. In December 2014, the ITA.
LI.CA data set included 6581 HCC patients. From these, according to the selection criteria of our down-staging 
protocol, 742 HCC-T3 patients not treated with LT were retained.
Cumulative incidences of the competing events of interest were calculated using the Fine and Gray competing 
risks approach using the STATA syntax stcrreg (StataCorp. Stata Statistical Software: Release 12.). When neces-
sary, factors identified having a p < 0.10 on simple (univariate) competing risk analysis were entered into a multi-
variable regression model. A p-value < 0.05 was considered statistically significant in all the analyses.
Statement of Ethics. Demographic, clinical, laboratory and imaging data of study patients were collected 
and analyzed in accordance with the Helsinki Declaration and Regional Ethics Committee under informed con-
sent of the patients.
Results
Pre- and post-LT features of the study population. Pre-operative clinical features were comparable 
among the four groups except for liver function, which was worst in the No-Down group (Table 1). As expected, 
the number and mean size of the nodules were different among groups. TACE was the most frequently adopted 
neo-adjuvant treatment, especially for patients undergoing the down-staging protocol. The histological evalua-
tion of explanted livers showed no cases with macro-vascular tumor invasion, and the rate of complete tumor 
necrosis did not differ among the groups (Table 2). As expected, the Down-not Achieved and the No-Down 
groups more frequently showed a T3 stage or higher (≥4 nodules of any size) and histological features of tumor 
aggressiveness, such as micro-vascular invasion and moderate/poor tumor differentiation.
Risk of drop-out during waiting time. In the whole population, the LT rate at 24 months was 75% and 
the drop-out rate during the waiting time 18%. The competing-risk analysis showed a higher risk of drop-out for 
Down-Achieved and Down-not Achieved compared to MC and No-Down, whereas predicted probabilities of LT 
remained roughly similar among the four groups (Fig. 1). In particular, the pooled predicted drop-out rate at 24 
months was 27.6% for Down-Achieved and Down-not Achieved patients, a figure significantly higher than that of 
MC and No-Down patients (9.2%, p < 0.001). Multivariate competing-risks analysis showed that the study group 
was the only significant variable associated with the exclusion from LT.
The median waiting time was not significantly different among the groups, as reported in Table 1, but consid-
ering the waiting time longer than 6 months, it was differently distributed (79% Down-Achieved, 47% Down-not 
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Achieved, 38% days No-Down and 64% MC, p < 0.005). The waiting time longer than 6 months was also statisti-
cally related to a higher rate of drop-out on the waiting list (8% vs. 26%, p < 0.001).
Recurrence rate, post-LT survival and intention to-treat survival. After a median follow-up of 60 
months, the post-LT overall recurrence rate was significantly different among groups, being 7.6% in MC, 20.9% in 
Down-Achieved, 31.6% in Down-not Achieved and 30.4% in No-Down patients (p < 0.001) (Fig. 2).
The 3-year overall survival of MC and Down-Achieved patients was 80%, better than in the other two groups. 
However, in Down-Achieved patients it dropped to about 60% at 5 years, becoming similar to the survival 
rates of Down-not Achieved and No-Down patients (Fig. 3). In particular, survival rates at 5 years were: 63% in 
Down-Achieved, 62% in Down-not Achieved, 63% in No-Down, and 77% in MC patients (p = n.s.). The only 
variable related to a lower recurrence rate and a better survival was the effective down-staging to T2 at the his-
tological evaluation of the explanted liver: recurrence rate = 7.8% vs. 26% (p < 0.001) and 5-year patient sur-
vival = 76% vs. 67% (p < 0.05). The waiting time longer than 6 months was not related to tumor recurrence and 
patient survival after LT.
The intention-to-treat analysis of survival showed similar results to patient survival after LT, at 3 years the 
survival of MC and Down-Achieved was equal to 82–83%, but in the last group it dropped to 64% at 5 years, as 
in the Down-not Achieved and No-Down groups (Fig. 4). The 5-year survival rate among groups did not show 
statistical differences and was: 64% in Down-Achieved, 60% in Down-not Achieved, 66% in No-Down, and 75% 
in MC patients (Fig. 4).
Comparison with ITA.LI.CA T3 patients. Survivals since listing for LT of Down-Achieved, No-Down 
and Down-not Achieved patients were compared to the outcome of T3 patients from the ITA.LI.CA database. 
These patients were selected following the criteria of our down-staging protocol. Multivariate competing-risk 
regression was adjusted for the covariates age and MELD at listing or, for ITA.LI.CA patients, at HCC diagno-
sis (see Supplementary Material), and predicted probabilities of death were plotted (Fig. 5). Notably, the pre-
dicted probability of death at 5 years for ITA.LI.CA T3 patients was 80%, whereas the corresponding figures of 
Down-Achieved, No-Down and Down-not Achieved patients were 30%, 33% and 43%, respectively (p < 0.001).









Down-Achieved Down-No Achieved No-Down
(n = 65) (n = 30) (n = 27) (n = 186)
Male, n (%) 60 (92.3) 26 (86.7) 18 (66.7) 160 (86.0) p = 0.02






(59) p = 0.3
Liver disease HCV + , n (%) 36 (55.5) 21 (70.0) 18 (66.7) 109 (58.6) p = 0.1
CHILD C, n (%) 13 (20.0) 5 (16.7) 15 (55.6) 44 (23.8) p = 0.001






(13) p = 0.05
AFP ng/dl median 9 10 10 10 p = 0.37
Waiting time median days 362 180 141 285 p = 0.7
Single HCC, n (%) 6 (9.2) 0 14 (51.9) 96 (51.6)
p = 0.001
2 HCC, n (%) 16 (24.6) 9 (30.0) 8 (29.6) 51 (27.4)
3 HCC, n (%) 11 (16.9) 3 (10.0) 5 (18.5) 39 (19.9)
4 HCC, n (%) 15 (23.1) 14 (46.7) — —
5 HCC, n (%) 17 (26.1) 4 (13.3) — —
1 HCC mean size ± SD (median) 3.7 ± 1.6 (4) 3.6 ± 1.3 (3.9) 2.8 ± 1.1 2.5 ± 0.9 p = 0.001
2 HCCs mean size ± SD (median) 2 ± 1 (1.9) 2.3 ± 0.9 (2.3) 1.3 ± 1.2 1.1 ± 0.9 p = 0.001
3 HCCs mean size ± SD (median) 1.4 ± 1.1 (1.2) 1.4 ± 1.1 (1.1) 0.8 ± 0.7 0.8 ± 0.7 p = 0.001
4 HCCs mean size ± SD (median) 1.1 ± 0.8 (1) 0.9 ± 0.7 (1) — — p = 0.001
5 HCCs mean size ± SD (median) 1 ± 1.8 (1) 0.8 ± 0.5 (0.6) — — p = 0.001
Pre-LT Treatment, n (%) 65 (100) 30 (100) 21 (77.8) 167 (89.8) p = 0.001
TACE, n (%)








1.8 ± 1.0 p = 0.002
PEI








1.2 ± 1.0 p = 0.19
RF mean ± SD procedure 28 (43.1) 1.5 ± 1.3 9 (30.0) 0.9 ± 0.3 8 (29.6) 1.1 ± 0.4
65 (34.9) 
1.3 ± 0.9 p = 0.49
LR for down-stage 18 (27.7) 4 (13.8) — — p = 0.001
Previous R0 LR — — 3 (11.1) 26 (14.1) P = 0.005
Table 1. Clinical features of patients on the waiting list divided according to the study population.
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Discussion
The current updated series of patients with a 5-year follow-up after LT showed that the down-staging of HCCs 
outside the MC criteria had a higher risk of tumor recurrence, but their outcome fulfilled both the “utility”19 and 
the “transplant benefit” principle18,20. In fact, their 5-year survival rate was >50% and remarkably higher than that 
of T3 HCCs treated with therapies other than LT.
Our previously published data, based on a median follow-up of 2.5 years, showed both patient survival and 
HCC recurrence rate after LT comparable between down-staged and MC patients6,8. Similar results were obtained 
by Yao et al. even with a longer follow-up9. The study population of Yao et al. was quite different from ours in 
both previous21 and present up-dated series. In particular, American patients undergoing down-staging more 
frequently had less aggressive tumor biology, as testified by the low rate of micro-vascular invasion and a better 
differentiation degree. Furthermore, they reported a few cases with a number of nodules >4 and a higher rate of 
complete tumor necrosis.
These differences likely explain why our results were poorer than those reported by Yao et al.9. A recent series 
reported by Llovet et al.22, in which the histological features were quite comparable to our data, showed a similar 
high rate of tumor recurrence.
Nonetheless, in the Llovet study and in our series a satisfactory 5-years survival after LT was observed.
Many authors, including ourselves, believe that the down-staging procedure makes it possible to select tumors 
with more favorable biology6,23. On the other hand, these data were not so evident in our study, where the histo-
logical examination of explanted livers showed a higher rate of micro-vascular tumor invasion and a poor differ-
entiation degree in down-staged patients. Furthermore, the no-Down group, which did not undergo neoadjuvant 
treatments due to liver failure, had a lower drop-out rate during the waiting time and a satisfactory survival after 









Down-Achieved Down-not Achieved No-Down
(n = 43) (n = 20) (n = 23) (n = 145)
 ≥ T3, n (%) 16 (37.2) 15 (75.0) 17 (73.9) 32 (22.1) p = 0.001
Grade of differentiation Well, n (%) 18 (42) 3 (15) 6 (26) 83 (57)
p = 0.001
Moderate-Poor, n (%) 25 (58) 17 (75) 17 (74) 62 (43)
Microvascular tumor invasion, n (%) 22 (51.2) 14 (70.0) 15 (65.2) 41 (28.3) p = 0.001
Complete necrosis, no viable tumor, n (%) 5 (11.6) 2 (10.0) 2 (8.7) 20 (13.8) p = 0.88
Table 2. Explant histological results divided according to the study population.
Figure 1. Competing risk analysis of the probability of drop-out and transplantation in the study groups.
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LT. The shorter waiting time of this group may be compared to the shorter waiting time reported by the recent 
series with living donor liver transplantation for HCC beyond Milan Criteria24.
Therefore, the present study fuels the debated issue of the minimal time to wait until eligibility for LT is 
achieved, in particular for HCC patients with a high MELD score.
The present report addresses some aspects explored by previous studies9,25, i.e. the outcome of HCC patients 
not treated by down-staging and those treated but not effectively down-staged. The definition of effective 
down-staging still remains controversial; we used a radiological response able to meet the conventional Milan cri-
teria, but any other radiological response could also be evaluated. These two groups (not treated for down-staging 
due to high MELD score or treated with down-staging without the expected response) showed a rate of post-LT 
tumor recurrence close to 30%, which was significantly higher than the recurrence found in cases fulfilling the 
conventional criteria or effectively down-staged. Nevertheless, the 5-year survival rate was >50% even in these 
patients, confirming the utility of LT, and the comparison with a cohort of patients with the same tumor stage, but 
treated without LT, showed a significant benefit18,20.
Figure 2. Kaplan-Meier probabilities of tumor recurrence by study populations.
Figure 3. Kaplan- Meier probabilities of patient survival by study populations.
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This last result indicates that, although we must pay the “price” of lower survival, LT remains a pursuable ther-
apeutic option for non- or ineffectively-down-staged patients, even in the light of the “equity” standpoint of organ 
allocation19. Moreover, the adoption of expanded criteria for HCC transplant will be favored by the recent advent 
of highly effective anti- HCV (hepatitis C virus) infection therapies that will decrease of the number of non HCC 
competing patients, candidates for LT due to liver failure. A word of caution is however needed, as our cases not 
suitable for down-staging (due to poor liver function), or in whom the procedure was unsatisfactory, fulfilled the 
Bologna down-staging selection criteria at baseline. Therefore, their acceptable post-LT survival cannot represent 
what is achievable in all T3 patients, suggesting instead that careful selection of these cases is needed in order to 
prevent the failure of the “utility” principle accomplishment.
Another important finding picked up thanks to the long follow-up of the current study was the signifi-
cant increased tumor recurrence rate in patients beyond MC at the histological analysis, regardless of their 
pre-operative group distribution. This highlights even more the importance of very careful imaging evaluation 
before LT in order to really identify cases with different risks of poor outcome. So, we stress, as in our previ-
ous report8, the relevance of up-to-date contrast-enhanced ultrasonography and magnetic resonance (MR) in 
order to evaluate the response to loco-regional treatments for patients outside the MC, but also for conventional 
cases who are treated during the waiting time. The discrepancy among radiological and histological findings may 
increase with the number of nodules: in our series, patients with >3 nodules (33 cases) effectively treated with 
down-staging and then transplanted, had a low recurrence rate, comparable to the conventional criteria. This 
group was twice as large as that reported by Yao’s study9 and it therefore adds more evidence to the efficacy of 
down-staging in patients with more than 3 nodules.
Although the prospective design of the down-staging protocol and the long follow-up are the strengths of our 
study, it suffers from some limitations.
The outcomes were retrospectively evaluated, even if the data were gathered in a prospective manner and 
they come from a single institution. There were relatively few study cases, mainly since the entire population 
Figure 4. Kaplan-Meier probabilities of intention-to-treat survival by study populations.
Figure 5. Multivariate competing-risk regression adjusted for covariates Age and MELD score at start and 
predicted probabilities of death among ITALICA, Down-Achieved, Down-not Achieved and No-Down groups.
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was dichotomized into 4 groups. Therefore, the reproducibility of our results needs further confirmation. 
Furthermore, other data are probably necessary for a final conclusion concerning the patients who did not 
achieve radiological down-staging and were transplanted or those who were transplanted without doing any 
down-staging procedures due to liver failure. These cases were discussed in a multidisciplinary meeting and the 
only strict criteria for exclusion were the AFP higher than 400 ng/dL and the absence of macro-vascular or biliary 
invasion. The AFP limit was probably the key selection for our satisfactory patient survival, as stressed by recent 
studies26,27 and it was the most effective biological marker behavior, available pre-operatively. The many other 
clinical and pathological variables relevant during the multidisciplinary discussion, like recipient age, history 
of disease, type of response to treatment, type of donor offered and so on, are still too difficult to include in an 
algorithm process.
In conclusion, our study measured the price to be paid by transplant patients outside conventional HCC 
criteria (and within the Bologna criteria) after effective or ineffective down-staging procedures. The long-term 
outcome of down-staging candidates was poorer than that achievable with the conventional criteria, particularly 
for cases not meeting the protocol. Nevertheless, it can be considered acceptable since it is much better than that 
obtained with non-LT treatments.
Appendix. Other members of the ITA.LI.CA Group. Department of Internal Medicine, Gastroenterology 
Unit, Policlinico San Martino, University of Genova: Alessandro Moscatelli, Gaia Pellegatta, Vincenzo Savarino; 
Department of Medicine and Surgery Sciences, University of Bologna: Maurizio Biselli, Paolo Caraceni, 
Marco Domenicali, Annagiulia Gramenzi, Donatella Magalotti, Carla Serra, Laura Venerandi, Marco Zoli; 
Gastroenterology Unit, University of Bologna, Bologna: Antonio Colecchia, Giovanni Marasco, Federico Ravaioli; 
Radiology Unit, Department of Diagnostic and Preventive Medicine, University of Bologna, Bologna: Alberta 
Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli; Gastrenterology Unit, Belcolle Hospital, Viterbo: 
Eugenio Caturelli, Paola Roselli, Valentina Lauria, Giorgio Pelecca; Medicine Unit, Viterbo: Serena Dell’Isola, 
Anna Maria Ialungo, Elena Rastrelli; Department of Internal and Specialistic Medicine, Gatsroenterology 
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